Next Article in Journal
Speckle Tracking-Derived Left Atrial Stiffness Predicts Clinical Outcome in Heart Failure Patients with Reduced to Mid-Range Ejection Fraction
Next Article in Special Issue
Prevalence and Comorbidity of Atopic Dermatitis in Children: A Large-Scale Population Study Based on Real-World Data
Previous Article in Journal
Which Child with Asthma is a Candidate for Biological Therapies?
Open AccessArticle

Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

1
Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria
2
Institute of Medical Statistics, Medical University Vienna, 1090 Vienna, Austria
3
Department of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, Austria
4
Department of Dermatology, Kepler University Hospital, 4020 Linz, Austria
5
Department of Soft Matter Physics, Institute for Experimental Physics, Johannes Kepler University, 4020 Linz, Austria
6
Department of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, Austria
7
Department of Dermatology, Wiener Neustadt Public Hospital, 2700 Wiener Neustadt, Austria
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 1241; https://doi.org/10.3390/jcm9041241
Received: 9 April 2020 / Revised: 18 April 2020 / Accepted: 22 April 2020 / Published: 24 April 2020
(This article belongs to the Special Issue Management of Atopic Dermatitis)
Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation. View Full-Text
Keywords: Dupilumab; atopic dermatitis; biologicals; conjunctivitis; rosacea-like folliculitis Dupilumab; atopic dermatitis; biologicals; conjunctivitis; rosacea-like folliculitis
Show Figures

Figure 1

MDPI and ACS Style

Quint, T.; Brunner, P.M.; Sinz, C.; Steiner, I.; Ristl, R.; Vigl, K.; Kimeswenger, S.; Neubauer, K.; Pirkhammer, D.; Zikeli, M.; Hoetzenecker, W.; Reider, N.; Bangert, C. Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. J. Clin. Med. 2020, 9, 1241. https://doi.org/10.3390/jcm9041241

AMA Style

Quint T, Brunner PM, Sinz C, Steiner I, Ristl R, Vigl K, Kimeswenger S, Neubauer K, Pirkhammer D, Zikeli M, Hoetzenecker W, Reider N, Bangert C. Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. Journal of Clinical Medicine. 2020; 9(4):1241. https://doi.org/10.3390/jcm9041241

Chicago/Turabian Style

Quint, Tamara; Brunner, Patrick M.; Sinz, Christoph; Steiner, Irene; Ristl, Robin; Vigl, Kornelia; Kimeswenger, Susanne; Neubauer, Katharina; Pirkhammer, Detlev; Zikeli, Martin; Hoetzenecker, Wolfram; Reider, Norbert; Bangert, Christine. 2020. "Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis" J. Clin. Med. 9, no. 4: 1241. https://doi.org/10.3390/jcm9041241

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop